News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Lynette Smith, PhD

Articles by Lynette Smith, PhD

This trial combines pembrolizumab and trabedersen to enhance treatment for advanced NSCLC, targeting TGF-β2 for improved patient outcomes.

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

ByOmar K. Abughanimeh, MBBS,Anthony E. Maida III, PhD, MA, MBA,Sanjive Qazi, PhD,Kate-Lynn Muir, DO,Bhavina Sharma MD,Lynette Smith, PhD,Apar Kishor Ganti, MD

October 30th 2025

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

ByOmar K. Abughanimeh, MBBS,Nicole A. Shonka, MD,Jane Meza, PhD,Lynette Smith, PhD,Irfan A. Vaziri, MD,Mehmet Sitki Copur, MD,Robin High, MBA,Kimberly Shields, BSN, RN,Holly DeSpiegelaere, BSN, RN,Anne Kessinger, MD,Apar Kishor Ganti, MD, MS

August 13th 2025

This study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.

Latest Updated Articles

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck
August 13th 2025
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
October 30th 2025

Trending on CancerNetwork

Obesity and Cancer Risk: The Evolving Role of GLP-1s in Oncology

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Binimetinib Tablets Receive Tentative FDA Approval in Melanoma/NSCLC